Company Overview of X-Chem, Inc.
X-Chem, Inc. operates independently of Pharmaceutical Product Development, LLC as of January 06, 2016.
100 Beaver Street Suite 101
Waltham, MA 02453
Key Executives for X-Chem, Inc.
X-Chem, Inc. does not have any Key Executives recorded.
X-Chem, Inc. Key Developments
Ono Pharmaceutical Co., Ltd. Enters into Collaboration Agreement with X-Chem, Inc
Mar 21 17
Ono Pharmaceutical Co., Ltd. announced that Ono and X-Chem, Inc. signed a collaboration agreement, focused on discovering novel small molecules targeting multiple promising, high-impact oncology targets. Under the agreement, Ono will pay to X-Chem an upfront payment, research and license fees, success-based milestones on the research and development progress, as well as royalties on sales of the products. X-Chem will apply their proprietary DEX TM libraries, which contain over 120 billion small molecules, toward the discovery of new drug leads against multiple oncology targets selected by Ono. Ono will have worldwide exclusive rights to develop and commercialize any pharmaceutical products arising out of the drug discovery collaboration.
X-Chem, Inc. Announces Strategic Collaboration with Astellas Pharma Across Multiple Therapeutic Areas
Mar 20 17
X-Chem, Inc. announced the signing of a broad drug discovery collaboration with Astellas Pharma Inc. (Astellas). The collaboration will enable the discovery of novel lead compounds for complex drug targets of interest to Astellas from X-Chem’s growing collection of DNA-encoded DEXTM libraries containing over 120 billion compounds. This new partnership is X-Chem’s expansive first-time alliance with a pharmaceutical company, and is aimed at tackling hard-to-drug targets across multiple therapeutic areas at Astellas. Under the terms of this multi-year agreement, X-Chem will receive an up-front payment of $16 million. X-Chem is eligible to receive research funding, as well as license and option fees as the drug discovery collaboration proceeds. Additionally, Astellas has the option to license compounds identified through this collaboration, and X-Chem will be entitled to pre-clinical, developmental, and commercial milestone payments on licensed compounds against each target. Milestone payments could amount to over $100 million per target, in addition to royalties based on sales of future products.
X-Chem, Inc. Expands Collaboration with Janssen Biotech, Inc. to Discover New Drug
Feb 15 17
X-Chem, Inc. announced that it has expanded its collaboration with Janssen Biotech, Inc. to discover new drug leads for the treatment of inflammatory disease. The multi-target expansion builds on the parties' existing discovery and license partnership, entered into in December 2014, and was facilitated by Johnson & Johnson Innovation. This latest agreement will apply X-Chem's DEX platform to the identification of novel modulators for challenging disease targets, following the licensing of multiple series of X-Chem-discovered small molecules by Janssen in 2016. Under the terms of the agreement, X-Chem receives an upfront payment and research funding, and is eligible to receive additional payments and royalties based on the achievement of clinical, regulatory and commercial milestones.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|